Literature DB >> 8325957

The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro.

T A Guise1, T Yoneda, A J Yates, G R Mundy.   

Abstract

Humoral hypercalcemia of malignancy is a multifactorial syndrome caused by the action of tumor-produced factors on target organs of bone, kidney, and intestine to disrupt normal calcium homeostasis. Although parathyroid hormone-related protein (PTHrP) plays an integral role in the syndrome, tumors also produce other hypercalcemic factors, such as transforming growth factor-alpha (TGF-alpha), which may modulate the effects of PTHrP. In order to determine if the effects of PTHrP on calcium homeostasis can be modulated by TGF-alpha, we have used a human squamous cell carcinoma cell line (RWGT2) which produces PTHrP alone and Chinese hamster ovarian (CHO) cells expressing only transfected human TGF-alpha complementary DNA (CHO/TGF-alpha). We studied the effects of these tumors on calcium homeostasis in nude mice bearing both tumors or each tumor alone. Whole blood ionized calcium concentrations (mean +/- SEM in mmol/L) were significantly higher in mice bearing both RWGT2 and CHO/TGF-alpha tumors (3.11 +/- 0.06, P < 0.05) when compared with mice bearing either RWGT2 alone (2.02 +/- 0.06), CHO/TGF-alpha alone (1.42 +/- 0.01), or RWGT2 and nontransfected CHO tumors (1.86 +/- 0.01). This enhanced effect was also observed using continuous PTHrP-(1-34) infusion (2 micrograms/day) in mice bearing CHO/TGF-alpha tumors. In addition, tumor cell conditioned media was tested for bone resorbing activity in organ cultures of fetal rat long bones previously incorporated with 45calcium (45Ca++). Conditioned medium at 0.1% (vol/vol) from either RWGT2 or CHO/TGF-alpha had no bone resorbing activity over control (%45Ca++ release, mean +/- SEM; control 23 +/- 1, RWGT2 19 +/- 1, CHO/TGF-alpha 23 +/- 1). However, the combination of 0.1% conditioned medium from RWGT2 and CHO/TGF-alpha significantly increased bone resorption (53 +/- 2, P < 0.05). These data demonstrate that the hypercalcemic effects of tumor-produced PTHrP are enhanced by TGF-alpha and that this effect may be due to increased bone resorption.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325957     DOI: 10.1210/jcem.77.1.8325957

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.

Authors:  Rachelle W Johnson; Mai P Nguyen; Susan S Padalecki; Barry G Grubbs; Alyssa R Merkel; Babatunde O Oyajobi; Lynn M Matrisian; Gregory R Mundy; Julie A Sterling
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

2.  Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases.

Authors:  Jun Yuan; Christian Ossendorf; Jan P Szatkowski; James T Bronk; Avudaiappan Maran; Michael Yaszemski; Mark E Bolander; Gobinda Sarkar; Bruno Fuchs
Journal:  Cancer Invest       Date:  2009-05       Impact factor: 2.176

Review 3.  The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.

Authors:  Élora Midavaine; Jérôme Côté; Philippe Sarret
Journal:  Cancer Metastasis Rev       Date:  2021-05-11       Impact factor: 9.264

4.  6-Thioguanine inhibition of parathyroid hormone-related protein expression is mediated by GLI2.

Authors:  Rachelle W Johnson; Alyssa R Merkel; Sabrina Danilin; Mai P Nguyen; Gregory R Mundy; Julie A Sterling
Journal:  Anticancer Res       Date:  2011-09       Impact factor: 2.480

Review 5.  EGFR signaling in breast cancer: bad to the bone.

Authors:  John Foley; Nicole K Nickerson; Seungyoon Nam; Kah Tan Allen; Jennifer L Gilmore; Kenneth P Nephew; David J Riese
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

6.  Immunolocalization of transforming growth factor alpha in normal human tissues.

Authors:  M E Christensen; S S Poulsen
Journal:  Histochem Cell Biol       Date:  1996-05       Impact factor: 4.304

7.  Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo.

Authors:  Wolfgang E Gallwitz; Theresa A Guise; Gregory R Mundy
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 8.  At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone.

Authors:  John Foley; Nicole Nickerson; David J Riese; Peter C Hollenhorst; Gwendolen Lorch; Anne M Foley
Journal:  Odontology       Date:  2012-06-10       Impact factor: 2.634

9.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.

Authors:  T A Guise; J J Yin; S D Taylor; Y Kumagai; M Dallas; B F Boyce; T Yoneda; G R Mundy
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

10.  Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone.

Authors:  Jennifer L Gilmore; Ryan M Gonterman; Keshav Menon; Gwendolen Lorch; David J Riese; Alex Robling; John Foley
Journal:  Mol Cancer Res       Date:  2009-10-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.